Developer docs
API playgroundTry for free, no card

Search company profiles

Rubix LS

Full company profile

uuid00023im

Namestring
Rubix LS
Legal namestring
Rubix Life Sciences
Websiteurl
rubixls.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Rubix LS (legal name Rubix Life Sciences) is a privately held, for-profit clinical research organization founded in 2016 and headquartered in Lawrence, Massachusetts, with 11–50 employees. The company provides full-service contract research organization (CRO) capabilities spanning pre-clinical studies through Phase II trials (with partnered Phase III/IV support), translational bridging services for early and late-stage evidence planning, and federal health and public health research programs. Its primary customer segments are early-stage biotechnology teams requiring lean proof-of-concept programs, established pharmaceutical sponsors needing Phase I/II execution with complex populations, and federal health agencies requiring public health research and federal contracting expertise.

The company's core technology stack centers on the Patient X Platform — an integrative, interfaceless patient engagement and data-collection solution capturing socioeconomic, behavioral, and cultural data — supported by the TRIDENT boots-on-the-ground workforce, mobile clinical sites, and the Evidence Convergence Platform. Rubix LS claims integration of 25M+ patient records spanning underserved and underrepresented communities, enabling evidence generation that addresses health equity gaps, Complete Response Letters citing inadequate representation, and payer pushback on real-world applicability. AI-driven digital-twin modeling for Project Panacea (a joint venture with TheraSyn Bio developing an investigational topical breast cancer therapy) represents the company's most technically distinctive capability, integrating transdermal absorption, breast-tissue distribution, and tumor-response dynamics in a 100-condition in-silico simulation.

Rubix LS generates revenue through professional services across its three pillars — CRO, translational bridging, and federal health research — under quote-based, scope-dependent pricing that is not publicly disclosed. The go-to-market motion is enterprise field sales targeting pharmaceutical sponsors, biotech companies, and federal agencies, supplemented by content marketing, white papers, and strategic partnership announcements. Recent strategic activity has accelerated meaningfully: the company joined ARPA-H's Investor Catalyst Hub (December 2024), the Equity 2030 Alliance (February 2025), formed the Project Panacea joint venture (2025), and announced a U.S.-Mexico cross-border alliance with Scirena BioVentures (June 2026). The company is led by Founder and CEO Reginald Swift, Ph.D., with Eric Egnet as Chairman and Americo Diaz as Engineering Director. Disclosed funding totals approximately $1.9M across rounds in 2017, 2020, and 2021, and the company has executed two acquisitions (Katalyst Labs in 2018, Clinbotics in 2020).

Short descriptiontext

Rubix LS is a privately held clinical research organization (CRO) providing translational bridging, full-service Phase I/II trial execution, and federal health research, with a differentiated focus on underrepresented patient populations through mobile clinical sites and a 25M+ patient data set.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLawrence, United States
HQ citystring
Lawrence
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical research services, contract research organization, translational research, patient recruitment, evidence generation
Industry4 codes
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAI
Patient Recruitment, Site Feasibility & Trial Enablement CROs
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs
NAICS code4 codes
  • Scientific Research and Development Services5417
  • Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)541715
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Other Scientific and Technical Consulting Services541690
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Research Organization (CRO)
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Contract Research Services (CRO)
TypeProfessional Services
Description

Full-service CRO capabilities from pre-clinical studies through Phase II, with partnered Phase III/IV support, including protocol development, regulatory strategy, site management, patient recruitment, safety monitoring, data management, and biostatistics

rubixls.com
2Translational Bridging Services
TypeProfessional Services
Description

Strategic evidence planning and feasibility assessments for early-stage assets, biomarker strategy, endpoint selection, and integrated evidence plans

rubixls.com
3Federal Health Research Programs
TypeProfessional Services
Description

Partnership with federal agencies on infectious disease surveillance, biodefense programs, and community health initiatives through government contracting

rubixls.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Rubix LS is a clinical research and evidence generation company that designs studies, runs trials, and produces real-world evidence using data from patient populations most underrepresented in research. It delivers full-service CRO capabilities from pre-clinical studies through Phase II, translational bridging and evidence strategy services, and federal health and public health research programs, leveraging 25M+ integrated patient records and mobile clinical infrastructure.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 90% trial retention rate in hard-to-reach populations
+2 more records
Product overview1 text field

Rubix LS operates as a Health Outcomes Architect company providing an integrated suite of clinical research and evidence generation services. The portfolio centers on three pillars: Translational Bridging (early/late translational research and evidence strategy), Contract Research Services (full-service CRO from pre-clinical through Phase II/III), and Federal Health & Public Health Research Programs. Key proprietary platforms include the Patient X Platform for patient engagement and data collection, and the TRIDENT boots-on-the-ground team for community-based recruitment and retention. The Evidence Convergence Platform synthesizes patient-context data with biological, environmental, and healthcare-access signals. Under Project Panacea (joint venture with TheraSyn Bio), the company is developing an investigational topical therapy for early-stage breast cancer using digital-twin modeling. Services are delivered with 25M+ integrated patient records spanning underserved communities, mobile clinical infrastructure, and 90% retention rates in hard-to-reach populations.

Product and service8 records
1Translational Bridging
Categorycore service
Description

Early and late translational research services designing decision-grade evidence to support safety, effectiveness, access, and value. Includes feasibility assessments, biomarker strategy, endpoint selection, and integrated evidence plans shaped by data from 25M+ patient records across underserved communities. Targeted at biotech and pharmaceutical sponsors.

2Contract Research Services (CRO)
Categorycore service
Description

Full-service CRO capabilities from pre-clinical studies through Phase II, with partnered Phase III/IV support. Handles protocol development, regulatory strategy, site management, patient recruitment, safety monitoring, data management, and biostatistics. Targets biotech and pharmaceutical sponsors requiring execution of clinical development programs.

3Federal Health & Public Health Research Programs
Categorycore service
Description

Partnership with federal agencies on infectious disease surveillance, biodefense programs, and community health initiatives. Applies scientific rigor to national and community-level decision-making with culturally informed engagement strategies and federal contracting experience.

4Patient X Platform
Categoryplatform
Description

An integrative, interfaceless platform designed to simplify patient engagement and optimize data collection for clinical research programs. Captures socioeconomic, behavioral, and cultural data to tailor recruitment and engagement strategies.

5TRIDENT (Boots-on-the-Ground Team)
Categoryservice capability
Description

A patient augmentation workforce that supports recruitment, retention, and social engagement in underserved communities. Designed to extend trial access to communities that traditional site networks do not reach.

6Mobile Clinical Sites
Categoryservice capability
Description

Mobile clinical infrastructure extending trial access to communities that traditional site networks do not reach. Supports 90% retention rate in hard-to-reach populations through community-embedded research infrastructure.

7Evidence Convergence Platform
Categoryplatform
Description

Infrastructure that maps where breast cancer biology, patient demand, exposure burden, comorbidity burden, and healthcare delivery friction intersect. Combines proprietary patient-context signals with biological, environmental, access, and patient-preference layers.

8Project Panacea
Categoryinvestigational product
Description

A novel topical therapy for early-stage, localized breast cancer (DCIS-first approach) developed in joint venture with TheraSyn Bio. Uses tissue-confirmed pharmacology strategy with digital-twin modeling to evaluate whether localized delivery can reach breast tissue, change expected biology, and limit systemic exposure.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Equity 2030 Alliance
Strategic tierMajorTypeOthersAnnounced on2025-02-07
Description

Joined the Equity 2030 Alliance, a worldwide initiative aimed at fast-tracking gender equity in science, technology, and finance by 2030. Alliance partners include UNFPA, WHO, USAID, UNAIDS, and PATH. Focus areas include improving healthcare delivery, driving data equity, and expanding access to life-saving care.

rubixls.com
Strategic tierMajorTypeOthersAnnounced on2024-12-31
Description

Selected as spoke member of the Investor Catalyst Hub, a regional hub of ARPANET-H nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H). Managed by VentureWell in the Greater Boston area, the hub-and-spoke model aims to accelerate commercialization of groundbreaking and accessible biomedical solutions.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-02-28
Description

Strategic partnership to develop better diagnostic tools for lung cancer screening and improve breast cancer screening programs, especially for women with dense breasts and Triple Negative Breast Cancer (TNBC), focusing on reaching underserved communities. Combines Rubix LS's culturally competent research capabilities with BioMark's liquid biopsy technology platform.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Joint venture for Project Panacea, a novel investigational topical breast cancer therapy. Combines synthetic biology with real-world patient data to develop a non-invasive treatment for early-stage, localized breast cancer. Rubix LS provides AI-driven digital twin modeling and preclinical-to-clinical translation capabilities while TheraSyn Bio contributes the topical gel therapeutic platform.

Strategic tierCoreTypeTechnology or Integration
Description

Strategic partnership to revolutionize early cancer detection through innovative interstitial fluid and aptamer technologies. Rubix LS contributes its culturally competent research capabilities and CLIA/CAP clinical laboratory capacity while Kiffik Biomedical provides aptamer-based diagnostic technology platforms.

6Scirena BioVentures
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic alliance to accelerate biotech development across the U.S.-Mexico corridor. Partnership announced June 2026, focusing on cross-border biotechnology collaboration and development initiatives.

rubixls.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

IQVIA is the world's largest CRO offering full-service clinical development, real-world evidence, and technology-enabled trial design across all phases. Comparable to Rubix LS as the dominant incumbent whose scale and global site network define the competitive landscape Rubix LS must navigate.

TypeDirect peer
Description

Medpace is a mid-to-large full-service CRO with strong therapeutic specialization in oncology, rare disease, and infectious disease, very similar to Rubix LS's positioning. Most relevantly comparable as a therapeutically-focused CRO that wins on scientific depth rather than scale alone.

TypeBroad incumbent
Description

Fortrea (spun out of Labcorp) is a large CRO offering full-service clinical development and clinical trial laboratory services. Comparable as a competitor in CRO services and central lab capability, including CLIA-certified lab operations similar to Rubix LS's CLIA/CAP footprint.

TypeEmerging player
Description

ObvioHealth is a decentralized clinical trial CRO using mobile sites and digital tools to reach patient populations outside traditional site networks. Comparable to Rubix LS's mobile clinical infrastructure and Patient X platform for community-based trial execution.

TypeBroad incumbent
Description

Parexel is a major private CRO with deep expertise in oncology, rare disease, and complex patient populations, directly aligned with Rubix LS's therapeutic-area focus. Comparable in serving biopharma sponsors needing complex protocol design and global trial execution.

TypeBroad incumbent
Description

ICON is a top-3 global CRO delivering full-service clinical research from Phase I through Phase IV across all major therapeutic areas. Direct competitor for the same pharma and biotech sponsor budgets that Rubix LS targets, with substantially greater scale and Phase III/IV capability.

TypeDirect peer
Description

Worldwide Clinical Trials is a mid-size, therapeutically-focused CRO with deep expertise in oncology, rare disease, and CNS, sharing Rubix LS's specialty positioning. Comparable as a similarly-sized competitor pursuing complex-population trials with scientific differentiation.

8Veristat
TypeDirect peer
Description

Veristat is a specialty CRO focused on complex clinical programs in oncology and rare disease for small to mid-sized biopharma sponsors. Closely comparable to Rubix LS as a therapeutically-specialized mid-market competitor serving similar biotech sponsor needs.

TypeBroad incumbent
Description

Syneos Health is a large CRO offering full-service clinical development and commercial services across all therapeutic areas. Comparable as a competitor for the same biopharma R&D outsourcing budgets.

TypeDirect peer
Description

CTI Clinical Trial is a specialty CRO with deep expertise in rare disease, hematology, and oncology, comparable in therapeutic focus and mid-market sponsor mix. Similar to Rubix LS in serving complex-population trials for biotech sponsors.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Rubix LS

Contract Research Organization (CRO)rubixls.com

Rubix LS is a privately held clinical research organization (CRO) providing translational bridging, full-service Phase I/II trial execution, and federal health research, with a differentiated focus on underrepresented patient populations through mobile clinical sites and a 25M+ patient data set.

What Rubix LS does

Rubix LS (legal name Rubix Life Sciences) is a privately held, for-profit clinical research organization founded in 2016 and headquartered in Lawrence, Massachusetts, with 11–50 employees. The company provides full-service contract research organization (CRO) capabilities spanning pre-clinical studies through Phase II trials (with partnered Phase III/IV support), translational bridging services for early and late-stage evidence planning, and federal health and public health research programs. Its primary customer segments are early-stage biotechnology teams requiring lean proof-of-concept programs, established pharmaceutical sponsors needing Phase I/II execution with complex populations, and federal health agencies requiring public health research and federal contracting expertise.

The company's core technology stack centers on the Patient X Platform — an integrative, interfaceless patient engagement and data-collection solution capturing socioeconomic, behavioral, and cultural data — supported by the TRIDENT boots-on-the-ground workforce, mobile clinical sites, and the Evidence Convergence Platform. Rubix LS claims integration of 25M+ patient records spanning underserved and underrepresented communities, enabling evidence generation that addresses health equity gaps, Complete Response Letters citing inadequate representation, and payer pushback on real-world applicability. AI-driven digital-twin modeling for Project Panacea (a joint venture with TheraSyn Bio developing an investigational topical breast cancer therapy) represents the company's most technically distinctive capability, integrating transdermal absorption, breast-tissue distribution, and tumor-response dynamics in a 100-condition in-silico simulation.

Rubix LS generates revenue through professional services across its three pillars — CRO, translational bridging, and federal health research — under quote-based, scope-dependent pricing that is not publicly disclosed. The go-to-market motion is enterprise field sales targeting pharmaceutical sponsors, biotech companies, and federal agencies, supplemented by content marketing, white papers, and strategic partnership announcements. Recent strategic activity has accelerated meaningfully: the company joined ARPA-H's Investor Catalyst Hub (December 2024), the Equity 2030 Alliance (February 2025), formed the Project Panacea joint venture (2025), and announced a U.S.-Mexico cross-border alliance with Scirena BioVentures (June 2026). The company is led by Founder and CEO Reginald Swift, Ph.D., with Eric Egnet as Chairman and Americo Diaz as Engineering Director. Disclosed funding totals approximately $1.9M across rounds in 2017, 2020, and 2021, and the company has executed two acquisitions (Katalyst Labs in 2018, Clinbotics in 2020).

Rubix LS firmographics

Firmographics
Name
Rubix LS
Legal name
Rubix Life Sciences
Website
https://rubixls.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Rubix LS is a privately held clinical research organization (CRO) providing translational bridging, full-service Phase I/II trial execution, and federal health research, with a differentiated focus on underrepresented patient populations through mobile clinical sites and a 25M+ patient data set.
Ownership category
akta.pro rank

Rubix LS industry classification

Industry
Product category
Contract Research Organization (CRO)
NAICS
Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Scientific and Technical Consulting Services (541690)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAI
Patient Recruitment, Site Feasibility & Trial Enablement CROs
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs

Keywords

  • Clinical research services
  • Contract research organization
  • Translational research
  • Patient recruitment
  • Evidence generation

Where Rubix LS is headquartered

Location

Headquarters

HQ city
Lawrence
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Rubix LS business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Contract Research Services (CRO): Full-service CRO capabilities from pre-clinical studies through Phase II, with partnered Phase III/IV support, including protocol development, regulatory strategy, site management, patient recruitment, safety monitoring, data management, and biostatistics
  2. Translational Bridging Services: Strategic evidence planning and feasibility assessments for early-stage assets, biomarker strategy, endpoint selection, and integrated evidence plans
  3. Federal Health Research Programs: Partnership with federal agencies on infectious disease surveillance, biodefense programs, and community health initiatives through government contracting

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Rubix LS product offering

Product offering

Core offering

Rubix LS is a clinical research and evidence generation company that designs studies, runs trials, and produces real-world evidence using data from patient populations most underrepresented in research. It delivers full-service CRO capabilities from pre-clinical studies through Phase II, translational bridging and evidence strategy services, and federal health and public health research programs, leveraging 25M+ integrated patient records and mobile clinical infrastructure.

Product overview

Rubix LS operates as a Health Outcomes Architect company providing an integrated suite of clinical research and evidence generation services. The portfolio centers on three pillars: Translational Bridging (early/late translational research and evidence strategy), Contract Research Services (full-service CRO from pre-clinical through Phase II/III), and Federal Health & Public Health Research Programs. Key proprietary platforms include the Patient X Platform for patient engagement and data collection, and the TRIDENT boots-on-the-ground team for community-based recruitment and retention. The Evidence Convergence Platform synthesizes patient-context data with biological, environmental, and healthcare-access signals. Under Project Panacea (joint venture with TheraSyn Bio), the company is developing an investigational topical therapy for early-stage breast cancer using digital-twin modeling. Services are delivered with 25M+ integrated patient records spanning underserved communities, mobile clinical infrastructure, and 90% retention rates in hard-to-reach populations.

Differentiator

Problem solved

Functional benefit

Products and services

  • Translational Bridging Early and late translational research services designing decision-grade evidence to support safety, effectiveness, access, and value. Includes feasibility assessments, biomarker strategy, endpoint selection, and integrated evidence plans shaped by data from 25M+ patient records across underserved communities. Targeted at biotech and pharmaceutical sponsors.
  • Contract Research Services (CRO) Full-service CRO capabilities from pre-clinical studies through Phase II, with partnered Phase III/IV support. Handles protocol development, regulatory strategy, site management, patient recruitment, safety monitoring, data management, and biostatistics. Targets biotech and pharmaceutical sponsors requiring execution of clinical development programs.
  • Federal Health & Public Health Research Programs Partnership with federal agencies on infectious disease surveillance, biodefense programs, and community health initiatives. Applies scientific rigor to national and community-level decision-making with culturally informed engagement strategies and federal contracting experience.
  • Patient X Platform An integrative, interfaceless platform designed to simplify patient engagement and optimize data collection for clinical research programs. Captures socioeconomic, behavioral, and cultural data to tailor recruitment and engagement strategies.
  • TRIDENT (Boots-on-the-Ground Team) A patient augmentation workforce that supports recruitment, retention, and social engagement in underserved communities. Designed to extend trial access to communities that traditional site networks do not reach.
  • Mobile Clinical Sites Mobile clinical infrastructure extending trial access to communities that traditional site networks do not reach. Supports 90% retention rate in hard-to-reach populations through community-embedded research infrastructure.
  • Evidence Convergence Platform Infrastructure that maps where breast cancer biology, patient demand, exposure burden, comorbidity burden, and healthcare delivery friction intersect. Combines proprietary patient-context signals with biological, environmental, access, and patient-preference layers.
  • Project Panacea A novel topical therapy for early-stage, localized breast cancer (DCIS-first approach) developed in joint venture with TheraSyn Bio. Uses tissue-confirmed pharmacology strategy with digital-twin modeling to evaluate whether localized delivery can reach breast tissue, change expected biology, and limit systemic exposure.

Quantifiable outcome

  • 90% trial retention rate in hard-to-reach populations
  • +2 more outcomes

Companies that use Rubix LS

Customer profile

Segments3 records

Ideal customer profiles3 records

Rubix LS technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability6 records

Feature5 records

Rubix LS partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered major and core.

  • Equity 2030 AlliancemajorOthers · 7 February 2025Joined the Equity 2030 Alliance, a worldwide initiative aimed at fast-tracking gender equity in science, technology, and finance by 2030. Alliance partners include UNFPA, WHO, USAID, UNAIDS, and PATH. Focus areas include improving healthcare delivery, driving data equity, and expanding access to life-saving care.
  • ARPA-H Investor Catalyst HubmajorOthers · 31 December 2024Selected as spoke member of the Investor Catalyst Hub, a regional hub of ARPANET-H nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H). Managed by VentureWell in the Greater Boston area, the hub-and-spoke model aims to accelerate commercialization of groundbreaking and accessible biomedical solutions.
  • BioMark Diagnostics Inc.coreStrategic or Co-development Partner · 28 February 2024Strategic partnership to develop better diagnostic tools for lung cancer screening and improve breast cancer screening programs, especially for women with dense breasts and Triple Negative Breast Cancer (TNBC), focusing on reaching underserved communities. Combines Rubix LS's culturally competent research capabilities with BioMark's liquid biopsy technology platform.
  • TheraSyn BiocoreStrategic or Co-development PartnerJoint venture for Project Panacea, a novel investigational topical breast cancer therapy. Combines synthetic biology with real-world patient data to develop a non-invasive treatment for early-stage, localized breast cancer. Rubix LS provides AI-driven digital twin modeling and preclinical-to-clinical translation capabilities while TheraSyn Bio contributes the topical gel therapeutic platform.
  • Kiffik BiomedicalcoreTechnology or IntegrationStrategic partnership to revolutionize early cancer detection through innovative interstitial fluid and aptamer technologies. Rubix LS contributes its culturally competent research capabilities and CLIA/CAP clinical laboratory capacity while Kiffik Biomedical provides aptamer-based diagnostic technology platforms.
  • Scirena BioVenturescoreStrategic or Co-development PartnerStrategic alliance to accelerate biotech development across the U.S.-Mexico corridor. Partnership announced June 2026, focusing on cross-border biotechnology collaboration and development initiatives.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Rubix LS competitors and assessment

Company assessment

Broad incumbents

  • IQVIA: IQVIA is the world's largest CRO offering full-service clinical development, real-world evidence, and technology-enabled trial design across all phases. Comparable to Rubix LS as the dominant incumbent whose scale and global site network define the competitive landscape Rubix LS must navigate.
  • Fortrea: Fortrea (spun out of Labcorp) is a large CRO offering full-service clinical development and clinical trial laboratory services. Comparable as a competitor in CRO services and central lab capability, including CLIA-certified lab operations similar to Rubix LS's CLIA/CAP footprint.
  • Parexel International: Parexel is a major private CRO with deep expertise in oncology, rare disease, and complex patient populations, directly aligned with Rubix LS's therapeutic-area focus. Comparable in serving biopharma sponsors needing complex protocol design and global trial execution.
  • ICON plc: ICON is a top-3 global CRO delivering full-service clinical research from Phase I through Phase IV across all major therapeutic areas. Direct competitor for the same pharma and biotech sponsor budgets that Rubix LS targets, with substantially greater scale and Phase III/IV capability.
  • Syneos Health: Syneos Health is a large CRO offering full-service clinical development and commercial services across all therapeutic areas. Comparable as a competitor for the same biopharma R&D outsourcing budgets.

Direct peers

  • Medpace: Medpace is a mid-to-large full-service CRO with strong therapeutic specialization in oncology, rare disease, and infectious disease, very similar to Rubix LS's positioning. Most relevantly comparable as a therapeutically-focused CRO that wins on scientific depth rather than scale alone.
  • Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-size, therapeutically-focused CRO with deep expertise in oncology, rare disease, and CNS, sharing Rubix LS's specialty positioning. Comparable as a similarly-sized competitor pursuing complex-population trials with scientific differentiation.
  • Veristat: Veristat is a specialty CRO focused on complex clinical programs in oncology and rare disease for small to mid-sized biopharma sponsors. Closely comparable to Rubix LS as a therapeutically-specialized mid-market competitor serving similar biotech sponsor needs.
  • CTI Clinical Trial & Consulting Services: CTI Clinical Trial is a specialty CRO with deep expertise in rare disease, hematology, and oncology, comparable in therapeutic focus and mid-market sponsor mix. Similar to Rubix LS in serving complex-population trials for biotech sponsors.

Emerging players

  • ObvioHealth: ObvioHealth is a decentralized clinical trial CRO using mobile sites and digital tools to reach patient populations outside traditional site networks. Comparable to Rubix LS's mobile clinical infrastructure and Patient X platform for community-based trial execution.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Rubix LS social profiles

Digital presence

Rubix LS compliance and trust

Trust signal

Compliance2 records

Rubix LS financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Rubix LS leadership team

Management profile

Number of profiles

Profiles3 records

Rubix LS funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Rubix LS M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rubix LS

What does Rubix LS do?

Rubix LS is a clinical research and evidence generation company that designs studies, runs trials, and produces real-world evidence using data from patient populations most underrepresented in research. It delivers full-service CRO capabilities from pre-clinical studies through Phase II, translational bridging and evidence strategy services, and federal health and public health research programs, leveraging 25M+ integrated patient records and mobile clinical infrastructure.

Is Rubix LS a public or private company?

Rubix LS is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Rubix LS founded?

Rubix LS was founded in 2016. It employs 11 to 50 people.

Where is Rubix LS based?

Rubix LS is headquartered in Lawrence, United States, in the North America region.

How does Rubix LS make money?

Three revenue lines are on record. Contract Research Services (CRO) is the primary driver. The others are translational Bridging Services and federal Health Research Programs.

Who are Rubix LS's main competitors?

Broad incumbents on record are IQVIA, Fortrea, Parexel International, ICON plc and Syneos Health. Direct peers are Medpace, Worldwide Clinical Trials, Veristat and CTI Clinical Trial & Consulting Services. ObvioHealth is listed as an emerging player.

Does Rubix LS have an API?

No public API is recorded for Rubix LS.

What industry is Rubix LS in?

Rubix LS's product category is Contract Research Organization (CRO). Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAI, Patient Recruitment, Site Feasibility & Trial Enablement CROs. Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireRubix LS Announces New Evidence-to-Product Initiatives in Collaboration with TheraSyn BioRubix LS announced new evidence-to-product initiatives with TheraSyn Bio, focusing on chronic kidney disease, colorectal cancer, and postpartum risk conversion. Each initiative is led by Rubix LS as an evidence asset, with Project Panacea as the anchor program. The workstreams are exploratory and not formal therapeutic candidates.EIN PresswireRubix LS Announces Evidence Convergence Roadmap, Beginning with Breast Cancer and Project PanaceaRubix LS announced its Evidence Convergence Roadmap, starting with breast cancer and Project Panacea, an investigational localized therapeutic program. The company has over 2.9 million U.S. patient-level breast cancer signals and plans to apply the model to maternal health, chronic kidney disease, and colorectal cancer.Business InsiderKiffik Biomedical and Rubix LS Partner to Revolutionize Cancer Diagnostics With Interstitial Fluid and Aptamer TechnologiesKiffik Biomedical and Rubix LS announced a partnership to develop a rapid colorectal cancer test combining interstitial fluid biomarker detection with aptamer-based precision medicine. The test aims to provide a non-invasive, accessible alternative to traditional screening, with development expected to accelerate toward an at-home diagnostic. The companies also plan to explore broader applications for other cancers and chronic diseases.YahooBioMark Partners with Rubix LS to Advance Blood-Based Cancer Screening in Underserved CommunitiesBioMark Diagnostics and Rubix LS announced a partnership to develop blood-based cancer screening tools for lung and breast cancer, targeting underserved communities. The collaboration will use mobile diagnostics and telehealth to improve access, with Rubix LS providing CLIA/CAP lab capacity and BioMark's liquid biopsy technology.